


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:45Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406115" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406115</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>eurojhisto</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Histochem</journal-id><journal-id journal-id-type="pmc-domain-id">1554</journal-id><journal-id journal-id-type="pmc-domain">eurojhisto</journal-id><journal-id journal-id-type="publisher-id">EJH</journal-id><journal-title-group><journal-title>European Journal of Histochemistry : EJH</journal-title></journal-title-group><issn pub-type="ppub">1121-760X</issn><issn pub-type="epub">2038-8306</issn><publisher><publisher-name>PAGEPress</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406115</article-id><article-id pub-id-type="pmcid-ver">PMC12406115.1</article-id><article-id pub-id-type="pmcaid">12406115</article-id><article-id pub-id-type="pmcaiid">12406115</article-id><article-id pub-id-type="pmid">40832995</article-id><article-id pub-id-type="doi">10.4081/ejh.2025.4228</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Aloe-emodin ameliorates chronic kidney disease fibrosis by inhibiting PI3K-mediated signaling pathway</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="M">Ming</given-names></name><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="W">Wenhui</given-names></name><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yao</given-names></name><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shang</surname><given-names initials="J">Jingying</given-names></name><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="W">Wenfan</given-names></name><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yan</surname><given-names initials="X">Xiaoming</given-names></name><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="P">Peng</given-names></name><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhou</surname><given-names initials="Y">Yabin</given-names></name><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="cor2" ref-type="corresp"/></contrib><role><bold>Contributions:</bold> MC, WZ, PL, YZ, conceived and designed the experiments; WZ, YC, MC, experiments performing, manuscript drafting; WW, XY, experiments guidance; PL, funding acquisition. All the authors read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work. Xiaoming Yan (yanxiaoming604@126.com) and Peng Liu (drliupeng@sina.cn) should be considered as co-corresponding authors.</role></contrib-group><aff id="aff001"><label>1</label><institution>Heilongjiang University of Chinese Medicine</institution>, <addr-line>Harbin</addr-line></aff><aff id="aff002"><label>2</label>Renal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin</aff><aff id="aff003"><label>3</label><institution>College of Traditional Chinese Medicine, Changchun University of Chinese Medicine</institution>, Changchun</aff><aff id="aff004"><label>4</label>Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing</aff><aff id="aff005"><label>5</label><institution>The First Affiliated Hospital of Heilongjiang University of Chinese Medicine</institution>, Harbin, <addr-line>China</addr-line></aff><author-notes><corresp id="cor1">*These authors contributed equally to this work</corresp><corresp id="cor2">Yabin Zhou, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, No. 24, Heping Street, Harbin, 150036, China. <email>zhouyabinhljzyydx@126.com</email></corresp><fn fn-type="COI-statement"><p>The authors declare no conflicts of interest.</p></fn><fn><p><bold>Ethics approval:</bold> all animal experiments in this study were conducted in accordance with the protocols approved by the Ethics Committee for Laboratory Animal Welfare of China-Japan Friendship Hospital (Approval No. zryhyy21-22-01-01). The date of approval is 3 January 2022.</p></fn><fn><p>
<italic toggle="yes">Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.</italic>
</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>17</day><month>6</month><year>2025</year></pub-date><volume>69</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">491917</issue-id><elocation-id>4228</elocation-id><history><date date-type="received"><day>07</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025, the Author(s)</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Licensee PAGEPress, Italy</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC <uri xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">BY-NC 4.0</uri>).</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="ejh-69-3-4228.pdf"/><abstract><p>Chronic kidney disease (CKD) impacts a vast number of individuals worldwide, culminating in renal fibrosis. Renal fibrosis serves as the main reason for end-stage renal failure. However, the current targeted treatment methods for renal fibrosis remain scarce. Aloe-emodin (AE) is a naturally occurring compound discovered in rhubarb and aloe. In this research, we investigated the underlying mechanisms of AE in adenine-induced mouse renal fibrosis models and TGF&#946;-1 stimulated renal tubular epithelial cells (HK-2). It was discovered that AE not only decelerated the decline of renal function in adenine-treated mice but also suppressed the expression of Collagen I and Fibronectin. Furthermore, network pharmacology analysis suggested that AE's treatment of renal fibrosis might function <italic toggle="yes">via</italic> the PI3K/Akt/GSK3&#946; signaling pathway. <italic toggle="yes">In vivo</italic> and <italic toggle="yes">in vitro</italic> Western blot and immunofluorescence findings demonstrate that AE significantly resists the advancement of renal fibrosis by inhibiting &#945;-smooth muscle actin and vimentin. Simultaneously, findings from 740Y-P (a PI3K agonist) and siRNA (PI3K) indicate that AE inhibits the expression of the PI3K/Akt/GSK3&#946; cascade by lowering PI3K's phosphorylation level. From a mechanistic perspective, through molecular docking and plasmid transfection, the specific base sequence of PI3K in HK-2 cells was altered for experimental validation. The outcomes illustrate that AE can directly bind with PI3K, inhibiting its activation, impeding the PI3K/Akt/GSK3&#946; signal transmission, thereby ultimately suppressing renal fibrosis progression. In conclusion, PI3K/Akt/GSK3&#946; is a potential therapeutic target for CKD-related renal fibrosis, making AE a promising new treatment alternative for this condition.</p></abstract><kwd-group><title>Key words</title><kwd>renal fibrosis</kwd><kwd>network pharmacology</kwd><kwd>PI3K/Akt/GSK3&#946; signaling pathway</kwd></kwd-group><funding-group><funding-statement><bold>Funding:</bold> this work was supported by the National Natural Science Foundation of China (No. 82274489), the Beijing Natural Science Foundation of China (No. 7232326) and the Heilongjiang Provincial Natural Science Foundation of China (No. LH2021H070).</funding-statement></funding-group><counts><fig-count count="7"/><table-count count="0"/><equation-count count="0"/><ref-count count="58"/><page-count count="14"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-1"><title>Introduction</title><p>Chronic kidney disease (CKD) impacts approximately 10% of people worldwide, presenting a growing health concern. The defining characteristic of this condition is the irreversible deterioration of kidney function over time, which ultimately progresses to uremia.<sup><xref rid="ref1" ref-type="bibr">1</xref></sup> Kidney fibrosis is a common consequence of progressive renal diseases.<sup><xref rid="ref2" ref-type="bibr">2</xref></sup> The process involves extracellular matrix (ECM) deposition, cellular scarring, and kidney structure destruction, eventually leading to end-stage kidney disease.<sup><xref rid="ref3" ref-type="bibr">3</xref></sup> Although there has been further understanding of the pathophysiology of CKD in recent years, current treatment strategies are still limited to slowing the disease&#8217;s progression rather than reversing established kidney fibrosis.<sup><xref rid="ref4" ref-type="bibr">4</xref></sup> Chinese Herbal Medicine (CHM), after decades of extensive research, has shown that some medicinal herbs, especially their extracted compounds, can treat various diseases and gradually elucidate their potential mechanisms.<sup><xref rid="ref5" ref-type="bibr">5</xref>,<xref rid="ref6" ref-type="bibr">6</xref></sup> Therefore, CHM may offer a novel and effective solution for managing CKD fibrosis.<sup><xref rid="ref7" ref-type="bibr">7</xref></sup></p><p>Aloe-emodin (AE) is an isomer of emodin, an anthraquinone derivative commonly found in aloe and rhubarb. It has garnered attention due to its wide range of biological activities, including immunomodulatory, anti-viral, anti-inflammatory, neuroprotective, anti-cancer and hepatoprotective properties.<sup><xref rid="ref8" ref-type="bibr">8</xref></sup> It shows remarkable potential in treating various diseases such as inflammatory diseases, growth disorders, sepsis, malaria, liver fibrosis, flu, type 2 diabetes and psoriasis.<sup><xref rid="ref9" ref-type="bibr">9</xref></sup> Notably, AE can inhibit the proliferation of transformed rat hepatic stellate cells by activating Caspase-9 in the mitochondrial pathway to induce apoptosis;<sup><xref rid="ref10" ref-type="bibr">10</xref></sup> it can also significantly suppress the production of type I collagen and the expression &#945;-smooth muscle actin (&#945;-SMA) in hepatic stellate cells.<sup><xref rid="ref11" ref-type="bibr">11</xref>,<xref rid="ref12" ref-type="bibr">12</xref></sup> Current research has revealed AE&#8217;s capability to combat fibrosis, offering new insights into therapeutic approaches for kidney fibrosis. Multiple mechanisms of kidney fibrosis have been confirmed. These include the TGF-&#946;/Smad,<sup><xref rid="ref13" ref-type="bibr">13</xref></sup> PI3K/Akt<sup><xref rid="ref14" ref-type="bibr">14</xref></sup>, Wnt/&#946;-Catenin,<sup><xref rid="ref15" ref-type="bibr">15</xref></sup> MAPK/ERK,<sup><xref rid="ref16" ref-type="bibr">16</xref></sup> and JAK/STAT<sup><xref rid="ref17" ref-type="bibr">17</xref></sup>signaling pathways. Among them, the PI3K/Akt signaling pathway is one of the key intracellular signaling pathways that modulate a variety of cellular processes such as proliferation, survival, growth, and metabolism.<sup><xref rid="ref18" ref-type="bibr">18</xref></sup> This pathway has a strong impact on the pathophysiological process of excessive deposition of ECM proteins<sup><xref rid="ref19" ref-type="bibr">19</xref></sup> - one of the hallmark features of fibrotic kidney disease. Liu <italic toggle="yes">et al.</italic> discovered that the Bupi Yishen formula inhibits the activity of PI3K/AKT signaling induced by adenine in rat kidneys and reduces the activation of PI3K/AKT signaling in TGF-&#946;1-induced human proximal renal tubular cells (HK-2) in a dose-dependent manner, thereby alleviating kidney fibrosis.<sup><xref rid="ref20" ref-type="bibr">20</xref></sup> Meanwhile, Glycogen synthase kinase 3 beta (GSK3&#946;) is an important downstream target in the PI3K/Akt signaling pathway and participates in various biological mechanisms.<sup><xref rid="ref21" ref-type="bibr">21</xref></sup> Research has found that inhibiting GSK3&#946; can reduce fibrosis in AKI mice.<sup><xref rid="ref22" ref-type="bibr">22</xref></sup> The results of these studies indicate that GSK3&#946; plays a role in the pathogenesis of renal fibrosis following injury. Furthermore, inhibition of GSK3&#946; prevented the progression of fibrosis even after injury had occurred, highlighting its importance as a therapeutic target. Based on the above analysis, we can hypothesize that modulating the activity of the PI3K/Akt/GSK3&#946; signaling axis can help control or reverse the progression of kidney fibrosis caused by other chronic kidney diseases. Therefore, our study proposed to delve into the protective effects of AE on CKD-induced renal fibrosis, focusing on its effects on the PI3K/Akt/GSK-3&#946; signaling axis. We used adenine-induced C57BL/6 mice and TGF-&#946;1-induced HK-2 cells to investigate the effects of AE on CKD fibrosis. Additionally, we investigated the molecular mechanisms of AE in CKD fibrosis and the role of the PI3K/Akt/GSK3&#946; signaling pathway using network pharmacology. This study aims to verify that AE improves renal fibrosis by inhibiting the PI3K/Akt/GSK3&#946; pathway.</p></sec><sec id="sec1-2"><title>Materials and Methods</title><sec id="sec2-1"><title>Prediction of targets</title><p>The targets of AE were acquired from the Traditional Chinese Medicine System Pharmacology Database (TCMSP, <ext-link xlink:href="https://old.tcmsp-e.com/tcmsp.php" ext-link-type="uri">https://old.tcmsp-e.com/tcmsp.php</ext-link>). The protein name was also normalized through the UniProtKB database (<ext-link xlink:href="http://www.uniprot.org" ext-link-type="uri">http://www.uniprot.org</ext-link>) with the species restriction &#8220;Homo sapiens&#8221;. GeneCards (<ext-link xlink:href="http://www.genecards.org" ext-link-type="uri">http://www.genecards.org</ext-link>) provided Disease-related targets. The search keywords were &#8220;Chronic kidney disease&#8221; and &#8220;Kidney fibrosis&#8221;, the category was &#8220;protein&#8221; and the species filter was &#8220;<italic toggle="yes">Homo sapiens</italic>&#8221;.</p><p>Construction of protein-protein interaction (PPI) network and biological analysis. The corresponding targets of AE, CKD, and kidney fibrosis were plotted on the Venn to obtain the intersecting targets. Subsequently, we imported the potentially interacting targets into the String database (<ext-link xlink:href="http://string-db.org/" ext-link-type="uri">http://string-db.org/</ext-link>) and constructed a PPI network with the parameters &#8220;<italic toggle="yes">Homo sapiens</italic>&#8221;, a minimum interaction score of 0.400, hiding unconnected points, and the rest of the parameters by default. Cytoscape software will be used to further analyze the PPI network, and the MCODE<sup><xref rid="ref23" ref-type="bibr">23</xref></sup> plug-in will be used to perform the computational analysis of the nodes in the PPI network to filter out a subset of the most important ones (Degree Cutoff: 2; Node Score Cutoff: 0.2; K-Core: 2; Max Depth: 100).</p><p>To investigate the biological functions and biological pathways of the intersecting targets, Gene Ontology (GO) enrichment analysis was conducted using the Metascape database (<ext-link xlink:href="http://www.metascape.org/" ext-link-type="uri">http://www.metascape.org/</ext-link>) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The results were presented through the CNSknowall platform (<ext-link xlink:href="https://cnsknowall.com" ext-link-type="uri">https://cnsknowall.com</ext-link>). A <italic toggle="yes">p</italic>-value &lt;0.05 was accepted.</p></sec><sec id="sec2-2"><title>Molecular docking</title><p>The PI3K protein crystal structure (PDB ID: 5DXT) was sourced from the RCSB PDB database (<ext-link xlink:href="https://www.rcsb.org/" ext-link-type="uri">https://www.rcsb.org/</ext-link>) and the small molecule 3D structure was sourced from the PubChem database (<ext-link xlink:href="https://pubchem.ncbi.nlm.nih.gov/" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/</ext-link>). Docking was achieved through the utilization of blind docking on the CB-DOCK2 online server (<ext-link xlink:href="https://cadd.labshare.cn/cb-dock2/php/blinddock.php" ext-link-type="uri">https://cadd.labshare.cn/cb-dock2/php/blinddock.php</ext-link>).<sup><xref rid="ref24" ref-type="bibr">24</xref></sup> The CB-DOCK2 system employs artificial neural networks for cavity probing and utilizes the Autodock Vina docking algorithm. All parameters of CB-DOCK2 are set to default, such as number of cavities for docking: 5. The results of the docking procedure will be selected based on the binding energy. Subsequent kinetic verification of binding stability will be conducted through force analysis and docking position assessment. Ligand-receptor force analysis was conducted with the aid of the PLIP online server (<ext-link xlink:href="https://plip-tool.biotec.tu-dresden.de/plip-web" ext-link-type="uri">https://plip-tool.biotec.tu-dresden.de/plip-web</ext-link>), while the ligand-receptor 3D conformation was visualised using Pymol software.</p></sec><sec id="sec2-3"><title><italic toggle="yes">In vivo</italic> study</title><p>Fifty 8-week-old male C57BL/6 mice (Viewsolid Biotechnologies, Beijing, China) were housed in specific pathogen-free (SPF) surroundings with 25&#176;C temperature, 65% relative humidity and a 12 h light/dark cycle, and were allowed to access water and food <italic toggle="yes">ad libitum</italic>. After compliant feeding, the mice were randomly divided equally into five groups as follows: Control, Control+AE (20 mg/kg/day), adenine (50 mg/kg/day), AE10 (10 mg/kg/day), AE20 (20 mg/kg/day).<sup><xref rid="ref25" ref-type="bibr">25</xref></sup> AE10 and AE20 were both administered in adenine were administered based on adenine. Adenine and AE were dissolved in purified water and 0.5% sodium carboxymethyl cellulose, respectively. Interventions were carried out for 1 week, during which time mice were collected in urine and subsequently euthanized humanely, followed by blood and tissue samples.</p></sec><sec id="sec2-4"><title>Histopathology and immunohistochemistry</title><p>Kidney tissue specimens were fixed in 4% paraformaldehyde (Servicebio, Wuhan, China) overnight at 4&#176;C, then dehydrated, cleared, and embedded in paraffin. Consecutive sections (2-5 &#956;m thick) were cut.<sup><xref rid="ref26" ref-type="bibr">26</xref></sup> For histology, sections underwent standard hematoxylin (G1004, Servicebio) and eosin (G1001, Servicebio) staining (H&amp;E) and Masson&#8217;s trichrome staining (G1006 kit, Servicebio) following established protocols.<sup><xref rid="ref27" ref-type="bibr">27</xref></sup> For immunohisto-chemistry (IHC), deparaffinized sections underwent antigen retrieval (citrate buffer, pH 6.0, 95&#176;C, 20 min), endogenous peroxidase blocking (3% H<sub>2</sub>O<sub>2</sub>, 15 min, RT), and blocking (5% BSA, 30 min, RT). Sections were incubated overnight at 4&#176;C with primary antibodies: Fibronectin (Rabbit polyclonal, 1:1500, GB114491-100, Servicebio) and Collagen I (Rabbit polyclonal, 1:1000, GB11022-3-100, Servicebio). Negative controls used PBS instead of primary antibody. After washing, sections were incubated with HRP-conjugated Goat Anti-Rabbit IgG secondary antibody (1:200, GB23303, Servicebio) for 50 min at RT. Signal was visualized with DAB (G1211-200T, Servicebio) followed by nuclear counter-staining with Mayer&#8217;s haematoxylin (G1004, Servicebio) for 1 min. Negative controls were conducted by omitting the primary antibody to ensure specificity of the staining. Slides were dehydrated, cleared, mounted, and examined under a light microscope (BX53, Olympus; Tokyo, Japan) with a 40x objective.<sup><xref rid="ref28" ref-type="bibr">28</xref></sup> For each sample, three randomly selected fields were analyzed to ensure representative data. Image analysis was conducted using ImageJ software to quantify the percentage of positively stained cells. Three randomly selected fields per sample were analyzed, and the average percentage of immune-positive cells was reported.</p></sec><sec id="sec2-5"><title>Cell culture and treatment</title><p>HK-2 cells were cultured in Dulbecco&#8217;s Modified Eagle&#8217;s Medium (DMEM)/F-12 containing 10% foetal bovine serum (FBS, CellMax, Australia) and 1% penicillin/streptomycin, in an incubator at 37&#176;C and 5% CO<sub>2</sub>. TGF-&#946;1 (10 ng/ml) induced HK-2 cells as an <italic toggle="yes">in vitro</italic> model of renal fibrosis. Then, the cells were treated with different levels of AE (CAS: 418-72-1, purity &gt;98.0%, cat: SA8200, Solarbio Science &amp; Technology, Beijing, China) and 740Y-P (30 &#956;M, MCE, Monmouth Junction, NJ, USA) for 24 h.<sup><xref rid="ref29" ref-type="bibr">29</xref></sup></p></sec><sec id="sec2-6"><title>Cell proliferation assay</title><p>The effect of AE on TGF-&#946;1-induced proliferation of HK-2 cells was assessed utilizing the Cell Counting Kit-8 (CCK-8) according to the instructions. 1&#215;10<sup>5</sup> HK-2 cells were inoculated into each well of a 96-well plate and waited until the cells were attached to the wall, then different concentrations of AE were added to treat the TGF-&#946;1-induced cells. After this, add 10 &#181;L of CCK-8 solution and keep for 1 h. Cell proliferation was analyzed according to the results measured by the zymography (450 nm). Furthermore, the results were replicated 8 times for each concentration.</p></sec><sec id="sec2-7"><title>Plasmid and siRNA transfection of cells</title><p>The coding sequence of PIK3CA was cloned into the pcDNA3.1 vector (Beyotime, Shanghai, China). The structure of the specific locus was changed using a rapid mutation system. Transfect the plasmid using the liposomal lip3000 method. Ensure that the cells are 70-80% covered in the 6-well plate before the experiment. Heat the DMEM water bath at 37&#176;C and place the transfection reagents and DNA plasmid at room temperature. Prepare two centrifuge tubes, add 125 &#181;L DMEM to each tube, add lipofectamine 3000 &#181;L to tube 1, and incubate at room temperature for 5 min; 2.5 &#181;g DNA plasmid was added to tube 2 and the two centrifuge tubes were mixed and left to stand at room temperature for 5 min. When the DNA liposomes were left to stand for 4 min, HK-2 cells to be transfected were taken out from the 37&#176;C incubator, and the DNA liposomes were incubated with DMEM. C incubator, gently over-washed with DMEM and then added DMEM 1.5 mL/well. When the time was up, 0.25 mL of DNA-liposome mixture was added drop by drop into the culture dish, and the dish was incubated in the incubator at 37&#176;C with 5% CO<sub>2</sub> for 4-6 h, then changed to 10% FBS-DMEM culture medium, and continued to incubate for 48 h to establish a stable cell line. PI3K (siRNA) was transfected into cells <italic toggle="yes">via</italic> Liposome 3000 (Mei5 Biotechnology; Beijing, China). The target sequences<sup><xref rid="ref30" ref-type="bibr">30</xref></sup> were sense 5'-GCUAUCCUCUGAACAACUATTdTdT-3' and antisense 5'-UAGUUGUUCAGA GGAUAGCTTdTdT-3'.</p></sec><sec id="sec2-8"><title>Immunofluorescence</title><p>Pre-treated tissues and cells were incubated overnight at 4&#176;C with primary antibodies, anti-P-Pi3k (1:100,17366S, Cell Signaling Technology, Danvers, MA, USA), anti-Pi3k (1:100, ab278545, Abcam, Cambridge, MA, USA), anti-Akt (1:200, 4691S, Cell Signaling Technology), anti-P-Akt (1:400, 4060S, Cell Signaling Technology), anti-GSK3p (1:200, K000041M, Solarbio) and anti-P-GSK3p (1:100, GB114582-100, Servicebio). The fluorescent secondary antibodies (1:800GB25301/GB28301, Servicebio) were added to the samples in a light-avoiding environment and incubated for 2 h at room temperature in the absence of light. Finally, DAPI (10 ug/mL) was incubated away from light for 5 min. Negative controls were conducted by omitting the primary antibody to ensure specificity of the staining. Immunofluorescence results were acquired through the use of laser confocal microscopy (LSM800, Zeiss, Oberkochen, Germany) in a 40x objective. Image analysis was performed using ImageJ software (National Institutes of Health). The precise methodology employed for immunofluorescence was consistent with that previously described.<sup><xref rid="ref31" ref-type="bibr">31</xref></sup> All experiments were repeated three times.</p></sec><sec id="sec2-9"><title>Western blotting assay</title><p>This experiment was performed using a-SMA (1:1000, 19245S, Cell Signaling Technology), Vimentin (1:1000, ab92547, Abcam), PI3k (1:100, sc-365290, Biotechnology, Santa Cruz, CA, USA), P-Pi3k (1:1000, ab278545, Abcam), GSK3P (1:1000, K000041M, Solarbio, Beijing, China), P-GSK3P (1:300, GB114582-100, Servicebio), Akt (1:1000, 4691S, Cell Signaling Technology), P-Akt (1:1000, 4060S, Cell Signaling Technology) and P-actin (1:10,000, sc-47778, Santa Cruz Biotechnology) antibodies. Specific signals were detected using a gel imaging system program (iBright CL1000, Thermo Fisher Scientific, Waltham, MA, USA), and the above signals were analyzed using Image J software. Specific steps were performed according to the previously described.<sup><xref rid="ref32" ref-type="bibr">32</xref></sup></p></sec><sec id="sec2-10"><title>Statistical analysis</title><p>All data are expressed as mean &#177; SEM values. To analyze the data, multiple comparisons were performed using ANOVA (oneway analysis of variance) and Dunnett&#8217;s <italic toggle="yes">t</italic>-test. A <italic toggle="yes">p</italic>-value of less than 0.05 was deemed to be statistically significant. The data were evaluated with the use of GraphPad Prism version 8.0 (GraphPad Prism Software, La Jolla, CA, USA).</p></sec></sec><sec id="sec1-3"><title>Results</title><sec id="sec2-11"><title>Acquisition of target points and construction of the PPI network</title><p>We obtained 23 biomolecular targets of AE and explored the chemical structure of AE in depth with the help of the PubChem database and KingDraw, obtaining <xref rid="fig001" ref-type="fig">Figure 1A</xref>. For CKD and renal fibrosis biomolecular targets, we obtained 12,850 and 7,975 respectively. By comparing the data of related proteins in three groups, we identified 21 common proteins (<xref rid="fig001" ref-type="fig">Figure 1B</xref>). With the help of the STRING database, we created a PPI network of the intersection proteins (<xref rid="fig001" ref-type="fig">Figure 1C</xref>). This network comprises 21 nodes, 75 edges, an average node degree of 7.14, and a local clustering coefficient of 0.676. The MCOD analysis of the PPI network conducted with Cytoscape software revealed the most core clustered sub-network, including CASP3, TP53, PTGS2, HSP90AB1, PIK3CA, IL1B, PRKCD, CDC42, TNF, MYC, and BAX, as shown in <xref rid="fig001" ref-type="fig">Figure 1D</xref>.</p></sec><sec id="sec2-12"><title>Enrichment analysis</title><p>To gain insight into the potential biological processes that AE may induce in renal fibrosis, the identified common genes were further analyzed. The GO analysis unveiled three main categories: biological processes (BP), cellular components (CC), and molecular functions (MF). Major biological processes include positive regulation of lipid catabolic process, programmed necrotic cell death, and positive regulation of an acute inflammatory response. Principal molecular functions identified were cytokine receptor binding, kinase regulator activity, protein kinase regulator activity, protease binding, and protein serine kinase activity. The primary cellular components involved were the nuclear periphery, neuronal cell body, cell body, transferase complex, <italic toggle="yes">etc</italic>. (<xref rid="fig001" ref-type="fig">Figure 1E</xref>). In furthermore, the top twenty pathways shown in <xref rid="fig001" ref-type="fig">Figure 1F</xref> were confirmed by KEGG enrichment analysis. It was found that eight signaling pathways, including the AGE-RAGE signaling pathway in diabetic complications, IL-17 signaling pathway, NF-kappa B signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, chemokine signaling pathway, hepatitis B, and human cytomegalovirus infection, play key roles either directly or indirectly in the occurrence and development of inflammation and fibrosis. Therefore, it is highly likely that AE can improve the progression of renal fibrosis through the aforementioned pathways.</p><fig position="anchor" id="fig001" orientation="portrait"><label>Figure 1.</label><caption><p>Network pharmacological analysis of aloe-emodin-associated proteins in CKD fibrosis. <bold>A</bold>) Structure of aloe-emodin. <bold>B</bold>) Venn diagram of overlapping proteins between CKD, kidney fibrosis and aloe-emodin related target genes. <bold>C</bold>) PPI network of overlapping target genes. <bold>D</bold>) PPI network key subset. <bold>E</bold>) GO enrichment analysis of predicted targets of overlapping proteins. <bold>F</bold>) KEGG analysis of predicted proteins of overlapping proteins. <bold>G</bold>) KEGG Diagram hsa04151.</p></caption><graphic position="float" orientation="portrait" xlink:href="ejh-69-3-4228-g001.jpg"/></fig><p>By utilizing the KEGG database to identify and screen the obtained signaling pathways, we discovered the PI3K-Akt signaling pathway that controls various biological reactions within cells (<xref rid="fig001" ref-type="fig">Figure 1G</xref>). GSK3&#946; is identified as one of its key downstream molecules. It has been reported that multiple AKT pathways are activated in lung fibrosis models,<sup><xref rid="ref33" ref-type="bibr">33</xref></sup> including the activation of the AKT/GSK3&#946; signaling pathway in bronchial epithelial cells induced by bleomycin.<sup><xref rid="ref34" ref-type="bibr">34</xref></sup> Based on these analyses, we selected the PI3K/Akt/GSK3&#946; signaling pathway to verify the preventive and therapeutic effects of AE on kidney fibrosis.</p></sec><sec id="sec2-13"><title>AE alleviates renal function, renal pathologic changes and renal fibrosis in adenine-induced mice</title><p>To evaluate the effect of AE on adenine-induced kidney injury in mice, we conducted oral administration of drugs to the mice for one week. The findings of the experimental study demonstrated that, in comparison to the adenine model group, the AE treatment regimen resulted in a notable reduction in serum creatinine (Scr), blood urea nitrogen (BUN) levels, and urine albumin/creatinine ratio (UACR), but there was no statistical difference between the high and low dose groups (<xref rid="fig002" ref-type="fig">Figure 2A</xref>). In <xref rid="fig002" ref-type="fig">Figure 2B</xref>, H&amp;E staining showed glomerular swelling in the model group, and inflammatory cell infiltration in the kidney interstitial area; collagen fiber deposition was evident in kidney tissue sections stained with Masson&#8217;s trichrome. By comparison, the kidney tissue pathology of the AE group was good. In addition, we performed IHC on the kidneys of the mice. The experiments showed that fibronectin and collagen I were widely deposited in the ECM of adenine mouse kidneys, and the addition of AE reversed the situation of kidney fibrosis (<xref rid="fig002" ref-type="fig">Figure 2C</xref>). Further analysis has shown that AE can be effective in decreasing the degree of glomerulosclerosis and interstitial fibrosis, and has a significant alleviating effect on adenine-induced kidney function damage and pathological changes in the kidney.</p><fig position="anchor" id="fig002" orientation="portrait"><label>Figure 2.</label><caption><p>The effect of AE in adenine-induced mice. <bold>A</bold>) MOR improve the level of Scr and BUN in blood; decreased the level of UACR in urine. <bold>B</bold>) H&amp;E staining reflects the extent of kidney damage in mice after 7 days of AE treatment; Masson's trichrome staining shows the extent of collagen fibril deposition in mice after 7 days of AE treatment. <bold>C</bold>) Immunohistochemical staining showed expression of fibronectin and collagen I after 7 days of AE treatment. Data are expressed as mean &#177; SD. n=10, *<italic toggle="yes">p</italic>&lt;0.05; **<italic toggle="yes">p</italic>&lt;0.01, ***<italic toggle="yes">p</italic>&lt;0.001 compared with the model group.</p></caption><graphic position="float" orientation="portrait" xlink:href="ejh-69-3-4228-g002.jpg"/></fig></sec><sec id="sec2-14"><title>AE interferes with the PI3K/AKT/GSK3&#946; signaling pathway in adenine-induced mice and ameliorates renal fibrosis</title><p>Network pharmacology revealed the potential mechanism of AE&#8217;s effect on the kidney. We noted through immunofluorescence staining that the expression of phosphorylated PI3K, AKT, and GSK3&#946; increased significantly in the kidney tissues of adenine mice. However, in the AE group, their expression levels were significantly reduced, close to the level of the control group (<xref rid="fig003" ref-type="fig">Figure 3A</xref>). Fortunately, our protein immunoblotting results were in line with this observation, showing significant increases in the ratios of p-PI3K/PI3K, p-Akt/Akt, and p-GSK3&#946;/GSK3&#946; (<xref rid="fig003" ref-type="fig">Figure 3B</xref>). Notably, the protein levels of the fibrotic molecules vimentin and &#945;-SMA were also significantly increased in the adenine group and dramatically reduced after AE treatment. However, increasing the dose of AE did not seem to significantly improve its therapeutic effect, with no statistical significance. The above results imply that AE may improve kidney fibrosis by inhibiting the activation of the PI3K/AKT/GSK3&#946; signaling pathway, which is likely related to the regulation of epithelial-mesenchymal transition.</p><fig position="anchor" id="fig003" orientation="portrait"><label>Figure 3.</label><caption><p>Regulation of PI3K/AKT/GSK3&#946; pathway by AE in adenine-induced mice. <bold>A</bold>) Immunofluorescence staining of p-PI3K, PI3K, p-Akt, Akt, p-GSK3&#946; and GSK3&#946; in Adenine-induced mice after 7 days of AE treatment. <bold>B</bold>) Protein expression levels of p-PI3K/PI3K, pAkt/Akt, p-GSK3&#946;/GSK3&#946;, Vimentin and &#945;-SMA in each specific group of mice after 7 days of AE treatment. *<italic toggle="yes">p</italic>&lt;0.05; **<italic toggle="yes">p</italic>&lt;0.01, ***<italic toggle="yes">p</italic>&lt;0.001 compared to the KKAy group.</p></caption><graphic position="float" orientation="portrait" xlink:href="ejh-69-3-4228-g003.jpg"/></fig><fig position="anchor" id="fig004" orientation="portrait"><label>Figure 4.</label><caption><p>AE improving renal fibrosis by inhibiting the PI3K/AKT/GSK3&#946; signaling pathway in TGF&#946;-1-stimulated HK-2 cells. <bold>A</bold>) The effect of AE on the proliferation of HK-2 cells. <bold>B</bold>) Immunofluorescence staining of p-PI3K, PI3K, p-Akt, Akt, p-GSK3&#946; and GSK3&#946; for each specific group. C) Protein expression levels of p-PI3K/PI3K, p-Akt/Akt, p-GSK3&#946;/GSK3&#946;, vimentin and &#945;-SMA in each specific group of HK-2 cells. *<italic toggle="yes">p</italic>&lt;0.05; **<italic toggle="yes">p</italic>&lt;0.01, ***<italic toggle="yes">p</italic>&lt;0.001 compared to TGF&#946;-1 group.</p></caption><graphic position="float" orientation="portrait" xlink:href="ejh-69-3-4228-g004ab.jpg"/><graphic position="float" orientation="portrait" xlink:href="ejh-69-3-4228-g004c.jpg"/></fig></sec><sec id="sec2-15"><title>AE inhibits PI3K/AKT/GSK3&#946; signaling pathway activation and ameliorates TGF-&#946;1-induced fibrosis in HK-2 cells</title><p>In order to clarify the potential mechanism of AE, we chose cell models for <italic toggle="yes">in vitro</italic> experiments to verify its anti-fibrotic effect. The results in <xref rid="fig004" ref-type="fig">Figure 4A</xref> show that compared to the TGF-&#946;1 group, cell viability increased significantly with various doses of AE, and the intervention concentrations of 5 &#956;M, 10 &#956;M, and 20 &#956;M worked the best. Therefore, these concentrations were used in subsequent experiments. First, we conducted immunofluorescence experiments. The experiment results show that changes in PI3K, AKT, and GSK3P in TGF-&#946;1-induced HK-2 cells were consistent with those in adenine mouse kidneys (<xref rid="fig004" ref-type="fig">Figure 4B</xref>). In Western blot experiments, we observed the changes of vimentin and &#945;-SMA in HK-2. The stimulation of TGF-p1 increased the expression of these proteins, intensifying the fibrosis of HK-2 cells. At the same time, PI3K was activated in HK-2. The ratio of p-PI3K/PI3K was highest in the model group, and then AKT and GSK3&#946; were also activated (<xref rid="fig004" ref-type="fig">Figure 4C</xref>). All the above conditions were inhibited after AE treatment. These changes reveal that AE delays the fibrosis process of TGF-&#946;1-induced HK-2 cells by inhibiting the activation of the PI3K/AKT/GSK3&#946; signaling pathway.</p><fig position="anchor" id="fig005" orientation="portrait"><label>Figure 5.</label><caption><p>Inhibition and activation of PI3K alters fibrosis in HK-2 cells. <bold>A</bold>) Protein levels of p-PI3K, PI3K, p-Akt, Akt, p-GSK3&#946;, GSK3&#946;, vimentin and &#945;-SMA in HK-2 cells in each group after 740Y-P treatment. <bold>B</bold>) Protein expression levels of p-PI3K/PI3K, p-Akt/Akt, p-GSK3&#946;/GSK3&#946;, Vimentin and &#945;-SMA in each specific group of HK-2 cells. <bold>C</bold>) Protein levels of PI3K, p-Akt, Akt, p-GSK3&#946;, GSK3&#946;, vimentin and &#945;-SMA in each group after PI3K silencing. <bold>D</bold>) Levels of p-PI3K/PI3K, p-Akt/Akt, p-GSK3&#946;/GSK3&#946;, vimentin and &#945;-SMA. *<italic toggle="yes">p</italic>&lt;0.05; **<italic toggle="yes">p</italic>&lt;0.01, ***<italic toggle="yes">p</italic>&lt;0.001 compared to TGF&#946;-1 group.</p></caption><graphic position="float" orientation="portrait" xlink:href="ejh-69-3-4228-g005.jpg"/></fig></sec><sec id="sec2-16"><title>Inhibition and activation of PI3K alters fibrosis in HK-2 cells</title><p>To further elucidate the role of AE and PI3K/AKT/GSK3&#946; signaling pathways in HK-2 cell fibrosis, we performed more in-depth experiments. First, we used the cell-permeable PI3K activator 740Y-P. As shown in <xref rid="fig005" ref-type="fig">Figure 5</xref> A,B, the PI3K/AKT/GSK3&#946; signaling pathway was fully activated and the levels of vimentin and &#945;-SMA was significantly upregulated in the fibrosis model cells; when 740Y-P and AE stimulated fibrosis model cells simultaneously, in terms of protein expression, AE counteracted the effect of 740Y-P in activating PI3K and inhibited PI3K activation. This suggests that AE may regulate PI3K/AKT/GSK3&#946; signaling pathway transduction and attenuate cellular fibrosis by inhibiting PI3K activation. We then transfected the siRNA of PI3K into HK-2 cells to silence its expression. In <xref rid="fig005" ref-type="fig">Figure 5</xref> C,D we can see that the ratio of p-PI3K/PI3K was significantly reduced after silencing compared to the control group, as was the expression of p-Akt/Akt and p-GSK3&#946;/GSK3&#946;. The differences between the TGF-&#946;1 and TGF-&#946;1+NC groups were not statistically significant. In addition, in comparison to the model group, the TGF-&#946;1+siRNA group demonstrated a notable reduction in the levels of Vimentin and &#945;-SMA, which was consistent with the results of the AE group. Nevertheless, in the TGF-&#946;1+siRNA+AE group, the superimposition of these two elements did not have a one-plus-one effect. The above results suggest that activation of PI3K promotes the progression of fibrosis, whereas inhibition of PI3K attenuates cellular fibrosis. When HK-2 cells received AE treatment, AE could slow down the fibrotic progression of the cells by inhibiting the activation of PI3K and thus modulating the PI3K/AKT/GSK3&#946; signaling pathway.</p></sec><sec id="sec2-17"><title>AE exerts fibrosis inhibition by binding to specific sites of PI3K</title><p>In the present study, molecular docking experiments were conducted to confirm the mechanism of action of AE and PI3K. On docking, it was observed that a specific interaction had been formed between AE and PI3K. The binding energy between ligand and receptor was calculated to be -9.0 kcal/mol using the Vina binding energy prediction algorithm based on the AMBER force field. The protein-ligand-formed complexes were analyzed for interaction forces relying on the PLIP server and the results were subsequently presented using the molecular modelling software Pymol. In <xref rid="fig006" ref-type="fig">Figure 6A</xref>, we have labelled a certain number of hydrogen bonds formed by proteins with the carboxyl groups of the compounds in red and those interacting with the &#960;-&#960; stack in orange, and have labelled specific interacting residues in the figure with the corresponding bond lengths in angstroms next to the dashed lines. Concurrently, the analysis of the ligand-protein mutual position, when considered in conjunction with the overall analysis, reveals that the ligand binds to the internal cavity of the protein with low free energy, forming a specific number of hydrogen bonds and a range of interactions. It can be postulated that the ligand and the receptor form a more stable complex.</p><fig position="anchor" id="fig006" orientation="portrait"><label>Figure 6.</label><caption><p>AE inhibits fibrosis by binding to PI3K. <bold>A</bold>) Predicted homology modelling structure of AE and PI3K protein binding site. <bold>B</bold>) Schematic diagram of PI3K mutation. <bold>C</bold>) PI3K-deficient HK-2 cells were re-expressed using the overexpressed plasmid, treated with AE for 24 h, and detected by CCK-8. *<italic toggle="yes">p</italic>&lt;0.05; **<italic toggle="yes">p</italic>&lt;0.01, ***<italic toggle="yes">p</italic>&lt;0.001 compared to TGF&#946;-1 group.</p></caption><graphic position="float" orientation="portrait" xlink:href="ejh-69-3-4228-g006.jpg"/></fig><p>On this basis, we constructed plasmids for PI3K mutants, which included TRP-780, TYR-836, GLU849, VAL-851, SER-854 and GLN-859 (<xref rid="fig006" ref-type="fig">Figure 6B</xref>). To establish PI3K-deficient HK-2 cells, we overexpressed with wild-type PI3K and mutant PI3K and treated with TGF-&#946;1 and AE, respectively. The results of the CCK-8 assay showed that wild-type PI3K significantly restored the reduced cellular activity of TGF-&#946;1 when stimulated by AE. However, PI3K-deficient HK-2 cells caused by mutant PI3K did not increase HK-2 cell activity after TGF-&#946;1 and AE stimulation, suggesting reduced sensitivity to AE (<xref rid="fig006" ref-type="fig">Figure 6C</xref>). Thus, AE can only exert its therapeutic effect by binding to specific sites of PI3K. Taken together, the results of previous experiments lead to the conclusion that AE inhibits the activity of PI3K by binding to it and ameliorates renal fibrosis by modulating the PI3K/AKT/GSK3&#946; signaling pathway.</p></sec></sec><sec id="sec1-4"><title>Discussion</title><p>CKD is a condition characterized clinically by a gradual deterioration in renal function. The underlying causes of CKD are numerous and diverse, including diabetes and hypertension.<sup><xref rid="ref35" ref-type="bibr">35</xref></sup> The typical lesion is a gradual covering of healthy renal cells with ECM proteins, resulting in renal fibrosis.<sup><xref rid="ref36" ref-type="bibr">36</xref></sup> However, no drugs have been approved to specifically target and directly treat renal fibrosis. Indirectly addressing renal fibrosis by controlling the progression of CKD is currently the dominant solution, including the use of standard medications such as ACE inhibitors, angiotensin II receptor blockers (ARBs) to control the causes of renal damage, and strict glycemic control in diabetic patients.<sup><xref rid="ref37" ref-type="bibr">37</xref></sup> The identification of effective new strategies for the treatment of kidney fibrosis is therefore of great importance. The results of recent research indicate that the active ingredients of Chinese medicines may have potential antifibrotic effects,<sup><xref rid="ref38" ref-type="bibr">38</xref>,<xref rid="ref39" ref-type="bibr">39</xref></sup> which reveals that we may be able to discover effective anti-renal fibrosis drugs from the wealth of Chinese medicinal resources.</p><p>AE, scientifically known as 1,8-dihydroxy-3-(hydroxymethyl) anthraquinone, with a chemical molecular formula of C<sub>15</sub>H<sub>10</sub>O<sub>5</sub> and a relative molecular mass of 270.23, is an anthraquinone compound extracted from the roots and rhizomes of rhubarb.<sup><xref rid="ref40" ref-type="bibr">40</xref></sup> A number of biological properties and potential therapeutic benefits have been ascribed to AE.<sup><xref rid="ref8" ref-type="bibr">8</xref></sup> Nevertheless, the impact of AE on renal fibrosis in CKD patients remains to be determined. Using network pharmacology and basic experiments, we predicted and assessed putative AE proteins and signaling pathways against kidney fibrosis. It was revealed that AE may attenuate renal fibrosis by inhibiting the PI3K/Akt/GSK3&#946; signaling pathway (Figure 9 C-F). <italic toggle="yes">In vivo</italic> and <italic toggle="yes">in vitro</italic> analyses showed that Aloe vera rhodopsin had an inhibitory effect on kinase activity and the corresponding molecules, which is consistent with the findings of Dou <italic toggle="yes">et al.<sup><xref rid="ref25" ref-type="bibr">25</xref></sup></italic>. The consistency between the different models emphasizes the therapeutic role of AE through this pathway, which coincides with the study by Liang <italic toggle="yes">et al.</italic><sup><xref rid="ref41" ref-type="bibr">41</xref></sup> and Cheng <italic toggle="yes">et al.</italic>,<sup><xref rid="ref42" ref-type="bibr">42</xref></sup> which provides a good basis for combating the progression of chronic renal failure.</p><fig position="anchor" id="fig007" orientation="portrait"><label>Figure 7.</label><caption><p>Schematic summary of AE amelioration of renal fibrosis through inhibition of the PI3K/AKT/GSK3&#946; signaling pathway.</p></caption><graphic position="float" orientation="portrait" xlink:href="ejh-69-3-4228-g007.jpg"/></fig><p>During the experiments, we proved for the first time that AE had an antifibrotic effect and protected against renal injury using adenine-induced CKD mice. AE ameliorated histopathological abnormalities in model mice (<xref rid="fig001" ref-type="fig">Figure 1</xref>), reduced collagen staining area and mesangial cell proliferation, and attenuated Scr, BUN, and UACR. Also, IHC showed that AE diminished the expression of fibrotic proteins, including fibronectin and collagen I, in the kidneys of adenine mice. Fibronectin and collagen I are two key ECM proteins, and the extent to which they are deposited in the kidney is directly correlated with damage to kidney structure and function.<sup><xref rid="ref43" ref-type="bibr">43</xref></sup> Notably, back in 2019, Cai <italic toggle="yes">et al.</italic> demonstrated that AE significantly inhibited human hepatic stellate cell proliferation and affected apoptosis,<sup><xref rid="ref44" ref-type="bibr">44</xref></sup> and that the activation and proliferation of hepatic stellate cells played a central role in the process of liver fibrosis.<sup><xref rid="ref45" ref-type="bibr">45</xref></sup> Recent research evidence increasingly suggests that epithelial-mesenchymal transition (EMT) is a crucial factor in the development of renal fibrosis, as transformed epithelial cells exacerbate the fibrotic process by secreting ECM proteins.<sup><xref rid="ref46" ref-type="bibr">46</xref></sup> Meanwhile, some scholars have found that AE can inhibit and reverse EMT in a variety of cancer cells,<sup><xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref48" ref-type="bibr">48</xref></sup> which makes us wonder whether AE can similarly inhibit or reverse EMT in renal tubular epithelial cells, or even reverse the process of renal fibrosis. Importantly, our study validated the capability of AE to decrease the expression of the EMT marker protein vimentin,<sup><xref rid="ref49" ref-type="bibr">49</xref></sup> attenuate kidney injury, and inhibit renal fibrosis. Furthermore, the specific molecular mechanism of its effect was analyzed through network pharmacology and molecular docking, and the close association of AE with the PI3K/Akt/GSK3&#946; signaling pathway was verified. The PI3K/AKT signaling pathway is of pivotal importance in the study of fibrosis, and there is an increasing recognition of its contribution to the fibrosis process. The reviews by Wang <italic toggle="yes">et al.</italic>
<sup><xref rid="ref50" ref-type="bibr">50</xref></sup> and Qin <italic toggle="yes">et al.</italic><sup><xref rid="ref51" ref-type="bibr">51</xref></sup> summarized and reported the findings of the PI3K/AKT pathway in idiopathic pulmonary fibrosis and cardiac fibrosis, respectively, and concluded that PI3K/AKT is a key signaling node during fibrosis, with potential significance for the development of novel antifibrotic strategies. In renal disease, a study by Liu <italic toggle="yes">et al.</italic><sup><xref rid="ref52" ref-type="bibr">52</xref></sup> found that Paeoniflorin was able to inhibit the proliferation and cell cycle progression of human mesenchymal cells (HMCs) and reduce the level of inflammatory factors and iNOS expression. In addition, the compound strongly inhibited the PI3K/AKT/GSK3&#946; pathway and potentiated the effects of PI3K inhibitors, while also resisting the activating effect of insulin-like growth factor 1 (IGF-1) on this pathway. GSK3&#946; is a key downstream signaling molecule of AKT, influencing inflammation and fibrosis.<sup><xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref54" ref-type="bibr">54</xref></sup> In addition, GSK3&#946; may represent a promising therapeutic target for renal fibrosis.<sup><xref rid="ref55" ref-type="bibr">55</xref></sup> These findings suggest that the PI3K/AKT/GSK3&#946; signaling pathway inhibits the activation and differentiation of HMCs and reduces the deposition of ECM, <italic toggle="yes">e.g.</italic>, collagen I, fibronectin, <italic toggle="yes">etc</italic>.,<sup><xref rid="ref56" ref-type="bibr">56</xref></sup> thereby inhibiting fibrosis formation. The results of these analyses are in perfect agreement with our experimental performance. In the present experiments, we found that AE not only inhibited adenine-induced renal injury in mice and attenuated the expression of the fibrosis indicators vimentin and &#945;-SMA, but also inhibited the overexpression of the PI3K/AKT/ GSK3&#946; pathway in an <italic toggle="yes">in vivo</italic> model (<xref rid="fig003" ref-type="fig">Figure 3</xref>). Notably, Dou <italic toggle="yes">et al.</italic> reported similar findings, confirming that inhibition of this signaling cascade by AE plays a key role in ameliorating renal fibrosis.<sup><xref rid="ref25" ref-type="bibr">25</xref></sup> More importantly, a series of functional analyses based on molecular docking data showed that AE failed to exert antifibrotic activity in PI3K-deficient HK-2 cells (<xref rid="fig006" ref-type="fig">Figure 6</xref>). As illustrated in the graph, the survival of HK-2 was decreased after TGF-p1 treatment, but cell survival was improved after AE treatment (<xref rid="fig006" ref-type="fig">Figure 6C</xref>). However, when the cells were treated with plasmid, the protective effect of AE on HK-2 lost its effect and cell survival decreased. The analysis of these results suggests that AE inhibits the activity of PI3K mainly by binding to PI3K, thus protecting renal function and improving fibrosis. Furthermore, the results indicate that PI3K may serve as a promising target for therapeutic intervention in the management of renal fibrosis.</p><p>Furthermore, network pharmacological analyses revealed that, besides the PI3K/AKT/GSK3P signaling pathway, the NF-KB signaling pathway and the glycan AGE-RAGE signaling pathway in diabetic complications play a crucial role in the pathological process of CKD fibrosis treated with AE. Activation of RAGE promotes NADPH oxidase-mediated reactive oxygen species (ROS) generation, which thereafter triggers endoplasmic reticulum stress, glomerular hypertrophy, podocyte injury, inflammatory responses and renal fibrosis.<sup><xref rid="ref57" ref-type="bibr">57</xref></sup> Furthermore, numerous studies have demonstrated that controlling the inflammatory response initiated by the NF-KB signaling pathway can successfully improve renal fibrosis.<sup><xref rid="ref28" ref-type="bibr">28</xref>,<xref rid="ref58" ref-type="bibr">58</xref></sup> These mechanisms are expected to provide new directions for studying AE in the treatment of renal fibrosis.</p><p>In summary, AE has a multifaceted therapeutic role in attenuating renal fibrosis. Meanwhile, our study suggests that the regulation of the PI3K/Akt/GSK3p pathway is central to its mechanism of action (<xref rid="fig007" ref-type="fig">Figure 7</xref>). Through this pathway, AE can inhibit PI3K activation in <italic toggle="yes">ex vivo</italic> models thereby hindering the PI3K/Akt/GSK3p signaling cascade and reducing the expression of fibrotic proteins such as Vimentin and a-SMA. More importantly, the above biological process is mediated by the binding of AE to specific sites of PI3K, thereby interrupting the signaling cascade and preventing the overproduction of matrix proteins. However, our study is still insufficient and the effects of AE on renal fibroblast activation and EMT, processes that are critical for the progression of renal fibrosis, should be further explored. With a more comprehensive grasp of these mechanisms, AE may indeed hold the key to innovative therapeutic strategies against CKD and renal fibrosis.</p></sec></body><back><sec sec-type="data-availability"><title>Availability of data and materials</title><p>The data supporting the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jha</surname><given-names>V</given-names></name><name name-style="western"><surname>Garcia-Garcia</surname><given-names>G</given-names></name><name name-style="western"><surname>Iseki</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Naicker</surname><given-names>S</given-names></name><name name-style="western"><surname>Plattner</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Chronic kidney disease: global dimension and perspectives</article-title>. <source>Lancet</source><year>2013</year>;<volume>382</volume>:<fpage>260</fpage>-<lpage>72</lpage>.<pub-id pub-id-type="pmid">23727169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)60687-X</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name></person-group>. <article-title>Kidney fibrosis: fundamental questions, challenges, and perspectives</article-title>. <source>Integr Med Nephrol Androl</source><year>2024</year>;<volume>11</volume>:<fpage>e24</fpage>-<lpage>00027</lpage>.</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosa</surname><given-names>BA</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>M</given-names></name><name name-style="western"><surname>Singh</surname><given-names>DK</given-names></name><name name-style="western"><surname>Choreno-Parra</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cole</surname><given-names>J</given-names></name><name name-style="western"><surname>Jimenez-Alvarez</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection</article-title>. <source>Commun Biol</source><year>2021</year>;<volume>4</volume>:<fpage>290</fpage>.<pub-id pub-id-type="pmid">33674719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-021-01829-4</pub-id><pub-id pub-id-type="pmcid">PMC7935909</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>YY</given-names></name><name name-style="western"><surname>Tan RZ</surname><given-names>Yu Y</given-names></name><name name-style="western"><surname>Niu</surname><given-names>YY</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name></person-group><article-title>LncRNA GAS5 protects against TGF-beta-induced renal fibrosis via the Smad3/miRNA-142-5p axis</article-title>. <source>Am J Physiol-Renal</source><year>2021</year>;<volume>321</volume>: <fpage>F517</fpage>-<lpage>26</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajprenal.00085.2021</pub-id><pub-id pub-id-type="pmid">34486400</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rui-Zhi</surname><given-names>T</given-names></name><name name-style="western"><surname>Hui</surname><given-names>D</given-names></name><name name-style="western"><surname>Jian-Chun</surname><given-names>L</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiao-Jia</surname><given-names>W</given-names></name><name name-style="western"><surname>Dan</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Astragalus mongholicus bunge and panax notoginseng formula (A&amp;P) combined with bifidobacterium contribute a renoprotective effect in chronic kidney disease through inhibiting macrophage inflammatory response in kidney and intestine</article-title>. <source>Front Physiol</source><year>2020</year>;<volume>11</volume>:<fpage>583668</fpage>.<pub-id pub-id-type="pmid">33329031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2020.583668</pub-id><pub-id pub-id-type="pmcid">PMC7729014</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Regulation of renal lipid deposition in diabetic nephropathy on morroniside via inhibition of NF-KB/TNF-a/SREBP1c signaling pathway</article-title>. <source>Chem-Biol Interact</source><year>2023</year>;<volume>385</volume>:<fpage>110711</fpage>.<pub-id pub-id-type="pmid">37769864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbi.2023.110711</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>M</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C</given-names></name><name name-style="western"><surname>Rao</surname><given-names>X.</given-names></name></person-group><article-title>Clinical characteristics and Chinese Medicine therapy of chronic kidney disease combined with cardiovascular disease</article-title>. <source>Integr Med Nephrol Androl</source><year>2023</year>;<volume>10</volume>:<fpage>e00023</fpage>.</mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Potential antineoplastic effects of Aloe-emodin: a comprehensive review</article-title>. <source>Am J Chinese Med</source><year>2014</year>;<volume>42</volume>:<fpage>275</fpage>-<lpage>88</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1142/S0192415X14500189</pub-id><pub-id pub-id-type="pmid">24707862</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>X</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>You</surname><given-names>L</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Aloe-emodin: A review of its pharmacology, toxicity, and pharmacokinetics</article-title>. <source>Phytother Res</source><year>2020</year>;<volume>34</volume>:<fpage>270</fpage>-<lpage>81</lpage>.<pub-id pub-id-type="pmid">31680350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ptr.6532</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lian</surname><given-names>LH</given-names></name><name name-style="western"><surname>Park</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Piao</surname><given-names>HS</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>DH</given-names></name></person-group>. <article-title>Aloe emodininduced apoptosis in t-HSC/Cl-6 cells involves a mitochondria-mediated pathway</article-title>. <source>Basic Clin Pharmacol</source><year>2005</year>;<volume>96</volume>:<fpage>495</fpage>-<lpage>502</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1742-7843.2005.pto_14.x</pub-id><pub-id pub-id-type="pmid">15910415</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>SL</given-names></name></person-group>. <article-title>Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies</article-title>. <source>New Engl J Med</source><year>1993</year>;<volume>328</volume>:<fpage>1828</fpage>-<lpage>35</lpage>.<pub-id pub-id-type="pmid">8502273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199306243282508</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>SW</given-names></name><name name-style="western"><surname>Nan</surname><given-names>JX</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Park</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>DH</given-names></name></person-group>. <article-title>Aloe emodin suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture</article-title>. <source>Pharmacol Toxicol</source><year>2002</year>;<volume>90</volume>:<fpage>193</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">12076313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1034/j.1600-0773.2002.900404.x</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>XM</given-names></name><name name-style="western"><surname>Nikolic-Paterson</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Lan</surname><given-names>HY</given-names></name></person-group>. <article-title>TGF-beta: the master regulator of fibrosis</article-title>. <source>Nat Rev Nephrol</source><year>2016</year>;<volume>12</volume>:<fpage>325</fpage>-<lpage>38</lpage>.<pub-id pub-id-type="pmid">27108839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneph.2016.48</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>XQ</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Su</surname><given-names>H</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Screening of active components in Astragalus mongholicus Bunge and Panax notoginseng formula for anti-fibrosis in CKD: nobiletin inhibits Lgals1/PI3K/AKT signaling to improve renal fibrosis</article-title>. <source>Renal Failure</source><year>2024</year>;<volume>46</volume>:<fpage>2375033</fpage>.<pub-id pub-id-type="pmid">38967135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/0886022X.2024.2375033</pub-id><pub-id pub-id-type="pmcid">PMC11229745</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>W</given-names></name><name name-style="western"><surname>Dai</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G</given-names></name><name name-style="western"><surname>Monga</surname><given-names>SP</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Wnt/beta-catenin signaling promotes renal interstitial fibrosis</article-title>. <source>J Am Soc Nephrol</source><year>2009</year>;<volume>20</volume>:<fpage>765</fpage>-<lpage>76</lpage>.<pub-id pub-id-type="pmid">19297557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2008060566</pub-id><pub-id pub-id-type="pmcid">PMC2663839</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name></person-group>. <article-title>Renal fibrosis: new insights into the pathogenesis and therapeutics</article-title>. <source>Kidney Int</source><year>2006</year>;<volume>69</volume>:<fpage>213</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="pmid">16408108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.ki.5000054</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>LH</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>X</given-names></name><name name-style="western"><surname>Xie</surname><given-names>KH</given-names></name><name name-style="western"><surname>Han</surname><given-names>RY</given-names></name><etal/></person-group>. <article-title>Hederagenin ameliorates renal fibrosis in chronic kidney disease through blocking ISG15 regulated JAK/STAT signaling</article-title>. <source>Int Immunopharmacol</source><year>2023</year>;<volume>118</volume>:<fpage>110122</fpage>.<pub-id pub-id-type="pmid">37023701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2023.110122</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Telomerase RNA TERC and the PI3K-AKT pathway form a positive feedback loop to regulate cell proliferation independent of telomerase activity</article-title>. <source>Nucleic Acids Res</source><year>2022</year>;<volume>50</volume>:<fpage>3764</fpage>-<lpage>76</lpage>.<pub-id pub-id-type="pmid">35323972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkac179</pub-id><pub-id pub-id-type="pmcid">PMC9023280</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Sox9 promotes renal tubular epithelial-mesenchymal transition and extracellular matrix aggregation via the PI3K/AKT signaling pathway</article-title>. <source>Mol Med Rep</source><year>2020</year>;<volume>22</volume>:<fpage>4017</fpage>-<lpage>30</lpage>.<pub-id pub-id-type="pmid">32901875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2020.11488</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J</given-names></name><name name-style="western"><surname>Jie</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name></person-group><article-title>Protective effects of the Bupi Yishen formula on renal fibrosis through PI3K/AKT signaling inhibition</article-title>. <source>J Ethnopharmacol</source><year>2022</year>;<volume>293</volume>: <fpage>115242</fpage>.<pub-id pub-id-type="pmid">35367329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2022.115242</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>M</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>WW</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name></person-group><article-title>Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation</article-title>. <source>J Biol Chem</source><year>2002</year>;<volume>277</volume>:<fpage>30935</fpage>-<lpage>41</lpage>.<pub-id pub-id-type="pmid">12063252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M201919200</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>SP</given-names></name><name name-style="western"><surname>Tao</surname><given-names>S</given-names></name><name name-style="western"><surname>Fields</surname><given-names>TA</given-names></name><name name-style="western"><surname>Webb</surname><given-names>S</given-names></name><name name-style="western"><surname>Harris</surname><given-names>RC</given-names></name><name name-style="western"><surname>Rao</surname><given-names>R.</given-names></name></person-group><article-title>Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice</article-title>. <source>Dis Model Mech</source><year>2015</year>;<volume>8</volume>:<fpage>931</fpage>-<lpage>40</lpage>.<pub-id pub-id-type="pmid">26092126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dmm.020511</pub-id><pub-id pub-id-type="pmcid">PMC4527294</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bader</surname><given-names>GD</given-names></name><name name-style="western"><surname>Hogue</surname><given-names>CW</given-names></name></person-group>. <article-title>An automated method for finding molecular complexes in large protein interaction networks</article-title>. <source>BMC Bioinform</source><year>2003</year>;<volume>4</volume>:<fpage>2</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-4-2</pub-id><pub-id pub-id-type="pmcid">PMC149346</pub-id><pub-id pub-id-type="pmid">12525261</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Gan</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>ZX</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name></person-group><article-title>CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting</article-title>. <source>Nucleic Acids Res</source><year>2022</year>;<volume>50</volume>:<fpage>W159</fpage>-<lpage>64</lpage>.<pub-id pub-id-type="pmid">35609983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkac394</pub-id><pub-id pub-id-type="pmcid">PMC9252749</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dou</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T</given-names></name><name name-style="western"><surname>Mu</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Aloe-emodin ameliorates renal fibrosis via inhibiting PI3K/Akt/mTOR signaling pathway in vivo and in vitro</article-title>. <source>Rejuv Res</source><year>2019</year>;<volume>22</volume>:<fpage>218</fpage>-<lpage>29</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/rej.2018.2104</pub-id><pub-id pub-id-type="pmid">30215298</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Abhar</surname><given-names>H</given-names></name><name name-style="western"><surname>Abd</surname><given-names>EFM</given-names></name><name name-style="western"><surname>Wadie</surname><given-names>W</given-names></name><name name-style="western"><surname>El-Tanbouly</surname><given-names>DM</given-names></name></person-group>. <article-title>Cilostazol disrupts TLR-4, Akt/GSK-3beta/CREB, and IL-6/JAK-2/STAT-3/SOCS-3 crosstalk in a rat model of Huntington's disease</article-title>. <source>PLoS One</source><year>2018</year>;<volume>13</volume>:<fpage>e0203837</fpage>.<pub-id pub-id-type="pmid">30260985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0203837</pub-id><pub-id pub-id-type="pmcid">PMC6160003</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>miR-106b-5p targeting SIX1 inhibits TGF-beta1-induced pulmonary fibrosis and epithelial-mesenchymal transition in asthma through regulation of E2F1</article-title>. <source>Int J Mol Med</source><year>2021</year>;<volume>47</volume>:<fpage>04855</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2021.4857</pub-id><pub-id pub-id-type="pmcid">PMC7846424</pub-id><pub-id pub-id-type="pmid">33495833</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Mechanism of dioscin ameliorating renal fibrosis through NF-kappaB signaling pathway-mediated inflammatory response</article-title>. <source>Mol Med Rep</source><year>2023</year>;<volume>27</volume>:<fpage>93</fpage>.<pub-id pub-id-type="pmid">36960871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2023.12980</pub-id><pub-id pub-id-type="pmcid">PMC10073814</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lai</surname><given-names>X</given-names></name><name name-style="western"><surname>Shao</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Graphene oxide induces p62/SQSTM-dependent apoptosis through the impairment of autophagic flux and lysosomal dysfunction in PC12 cells</article-title>. <source>Acta Biomater</source><year>2018</year>;<volume>81</volume>:<fpage>278</fpage>-<lpage>92</lpage>.<pub-id pub-id-type="pmid">30273743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2018.09.057</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xi</surname><given-names>R</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Hui</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>HPV16 E6-E7 induces cancer stem-like cells phenotypes in esophageal squamous cell carcinoma through the activation of PI3K/Akt signaling pathway in vitro and in vivo</article-title>. <source>Oncotarget</source><year>2016</year>;<volume>7</volume>:<fpage>57050</fpage>-<lpage>65</lpage>.<pub-id pub-id-type="pmid">27489353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.10959</pub-id><pub-id pub-id-type="pmcid">PMC5302972</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>RZ</given-names></name><name name-style="western"><surname>Li</surname><given-names>JC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lei</surname><given-names>XY</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>BAY61-3606 protects kidney from acute ischemia/reperfusion injury through inhibiting spleen tyrosine kinase and suppressing inflammatory macrophage response</article-title>. <source>Faseb J</source><year>2020</year>;<volume>34</volume>: <fpage>15029</fpage>-<lpage>46</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.202000261RRR</pub-id><pub-id pub-id-type="pmid">32964547</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>J</given-names></name><name name-style="western"><surname>Meng</surname><given-names>XM</given-names></name><name name-style="western"><surname>Huang</surname><given-names>XR</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AC</given-names></name><name name-style="western"><surname>Feng</surname><given-names>YL</given-names></name><name name-style="western"><surname>Hui</surname><given-names>DS</given-names></name><etal/></person-group>. <article-title>miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice</article-title>. <source>Mol Ther</source><year>2012</year>;<volume>20</volume>:<fpage>1251</fpage>-<lpage>60</lpage>.<pub-id pub-id-type="pmid">22395530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2012.36</pub-id><pub-id pub-id-type="pmcid">PMC3369297</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qin</surname><given-names>H</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xia</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Blocking TBK1 alleviated radiation-induced pulmonary fibrosis and epithelial-mesenchymal transition through Akt-Erk inactivation</article-title>. <source>Exp Mol Med</source><year>2019</year>;<volume>51</volume>:<fpage>1</fpage>-<lpage>17</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-019-0240-4</pub-id><pub-id pub-id-type="pmcid">PMC6465273</pub-id><pub-id pub-id-type="pmid">30988282</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Bleomycin-induced nuclear factor-kappaB activation in human bronchial epithelial cells involves the phosphorylation of glycogen synthase kinase 3beta</article-title>. <source>Toxicol Lett</source><year>2009</year>;<volume>187</volume>:<fpage>194</fpage>-<lpage>200</lpage>.<pub-id pub-id-type="pmid">19429264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxlet.2009.02.023</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>NR</given-names></name><name name-style="western"><surname>Fatoba</surname><given-names>ST</given-names></name><name name-style="western"><surname>Oke</surname><given-names>JL</given-names></name><name name-style="western"><surname>Hirst</surname><given-names>JA</given-names></name><name name-style="western"><surname>O'Callaghan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Lasserson</surname><given-names>DS</given-names></name><etal/></person-group>. <article-title>Global prevalence of chronic kidney disease - A systematic review and meta-analysis</article-title>. <source>PLoS One</source><year>2016</year>;<volume>11</volume>:<fpage>e0158765</fpage>.<pub-id pub-id-type="pmid">27383068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0158765</pub-id><pub-id pub-id-type="pmcid">PMC4934905</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Nephropathy 1st inhibits renal fibrosis by activating the PPARgamma signaling pathway</article-title>. <source>Front Pharmacol</source><year>2022</year>;<volume>13</volume>:<fpage>992421</fpage>.<pub-id pub-id-type="pmid">36339588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.992421</pub-id><pub-id pub-id-type="pmcid">PMC9635840</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walther</surname><given-names>CP</given-names></name><name name-style="western"><surname>Winkelmayer</surname><given-names>WC</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>PA</given-names></name><name name-style="western"><surname>Virani</surname><given-names>SS</given-names></name><name name-style="western"><surname>Navaneethan</surname><given-names>SD</given-names></name></person-group>. <article-title>Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease</article-title>. <source>Nephrol Dial Transpl</source><year>2021</year>;<volume>36</volume>:<fpage>1893</fpage>-<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfaa300</pub-id><pub-id pub-id-type="pmcid">PMC8633426</pub-id><pub-id pub-id-type="pmid">33367872</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>YH</given-names></name><name name-style="western"><surname>Deng</surname><given-names>HF</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>NN</given-names></name><name name-style="western"><surname>Yue</surname><given-names>LX</given-names></name><etal/></person-group>. <article-title>Ginsenoside Rb1 ameliorated bavachin-induced renal fibrosis via suppressing Bip/eIF2alpha/CHOP signaling-mediated EMT</article-title>. <source>Front Pharmacol</source><year>2022</year>;<volume>13</volume>:<fpage>872474</fpage>.<pub-id pub-id-type="pmid">35873571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.872474</pub-id><pub-id pub-id-type="pmcid">PMC9304982</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Diao</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Emodin alleviates cardiac fibrosis by suppressing activation of cardiac fibroblasts via upregulating metastasis associated protein 3</article-title>. <source>Acta Pharm Sin B</source><year>2019</year>;<volume>9</volume>:<fpage>724</fpage>-<lpage>33</lpage>.<pub-id pub-id-type="pmid">31384533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2019.04.003</pub-id><pub-id pub-id-type="pmcid">PMC6664101</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Shu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Aloe emodin relieves Ang II-induced endothelial junction dysfunction via promoting ubiquitination mediated NLRP3 inflammasome inactivation</article-title>. <source>J Leukocyte Biol</source><year>2020</year>;<volume>108</volume>:<fpage>1735</fpage>-<lpage>46</lpage>.<pub-id pub-id-type="pmid">32573820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/JLB.3MA0520-582R</pub-id><pub-id pub-id-type="pmcid">PMC7754316</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jing</surname><given-names>Z</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3beta signaling pathway</article-title>. <source>Biochem Bioph Res Co</source><year>2015</year>;<volume>463</volume>:<fpage>70</fpage>-<lpage>5</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2015.05.020</pub-id><pub-id pub-id-type="pmid">25986738</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy</article-title>. <source>Free Radical Bio Med</source><year>2016</year>;<volume>93</volume>:<fpage>94</fpage>-<lpage>109</lpage>.<pub-id pub-id-type="pmid">26849944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2016.02.002</pub-id><pub-id pub-id-type="pmcid">PMC7446394</pub-id></mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eddy</surname><given-names>AA</given-names></name></person-group>. <article-title>Molecular basis of renal fibrosis</article-title>. <source>Pediatr Nephrol</source><year>2000</year>;<volume>15</volume>:<fpage>290</fpage>-<lpage>301</lpage>.<pub-id pub-id-type="pmid">11149129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s004670000461</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>FF</given-names></name><name name-style="western"><surname>Bian</surname><given-names>YQ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>XL</given-names></name><name name-style="western"><surname>Yang</surname><given-names>MD</given-names></name><etal/></person-group>. <article-title>Yinchenhao decoction suppresses rat liver fibrosis involved in an apoptosis regulation mechanism based on network pharmacology and transcriptomic analysis</article-title>. <source>Biomed Pharmacother</source><year>2019</year>;<volume>114</volume>:<fpage>108863</fpage>.<pub-id pub-id-type="pmid">30991286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2019.108863</pub-id></mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>miR-455-3p alleviates hepatic stellate cell activation and liver fibrosis by suppressing HSF1 expression</article-title>. <source>Mol Ther-Nucl Acids</source><year>2019</year>;<volume>16</volume>:<fpage>758</fpage>-<lpage>69</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2019.05.001</pub-id><pub-id pub-id-type="pmcid">PMC6539335</pub-id><pub-id pub-id-type="pmid">31150929</pub-id></mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Feng</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Runt-related transcription factor 1 (RUNX1) promotes TGF-beta-induced renal tubular epithelial-to-mesenchymal transition (EMT) and renal fibrosis through the PI3K subunit p110delta</article-title>. <source>eBioMedicine</source><year>2018</year>;<volume>31</volume>:<fpage>217</fpage>-<lpage>25</lpage>.<pub-id pub-id-type="pmid">29759484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2018.04.023</pub-id><pub-id pub-id-type="pmcid">PMC6013935</pub-id></mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>M</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L</given-names></name><name name-style="western"><surname>Feng</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Sensitization of non-small cell lung cancer cells to gefitinib and reversal of epithelial-mesenchymal transition by aloeemodin via PI3K/Akt/TWIS1 signal blockage</article-title>. <source>Front Oncol</source><year>2022</year>;<volume>12</volume>:<fpage>908031</fpage>.<pub-id pub-id-type="pmid">35677158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.908031</pub-id><pub-id pub-id-type="pmcid">PMC9168594</pub-id></mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>JW</given-names></name><name name-style="western"><surname>Hung</surname><given-names>CM</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YC</given-names></name><name name-style="western"><surname>Ho</surname><given-names>CT</given-names></name><name name-style="western"><surname>Kao</surname><given-names>JY</given-names></name><name name-style="western"><surname>Way</surname><given-names>TD</given-names></name></person-group>. <article-title>Aloeemodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells</article-title>. <source>Oncotarget</source><year>2016</year>;<volume>7</volume>:<fpage>58915</fpage>-<lpage>30</lpage>.<pub-id pub-id-type="pmid">27391337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.10410</pub-id><pub-id pub-id-type="pmcid">PMC5312285</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>BMS-345541 inhibits airway inflammation and epithelial-mesenchymal transition in airway remodeling of asthmatic mice</article-title>. <source>Int J Mol Med</source><year>2018</year>;<volume>42</volume>:<fpage>1998</fpage>-<lpage>2008</lpage>.<pub-id pub-id-type="pmid">30015827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2018.3762</pub-id><pub-id pub-id-type="pmcid">PMC6108878</pub-id></mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>He</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis</article-title>. <source>Acta Pharm Sin B</source><year>2022</year>;<volume>12</volume>:<fpage>18</fpage>-<lpage>32</lpage>.<pub-id pub-id-type="pmid">35127370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2021.07.023</pub-id><pub-id pub-id-type="pmcid">PMC8799876</pub-id></mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>W</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><name name-style="western"><surname>Massey</surname><given-names>IY</given-names></name></person-group>. <article-title>Role of PI3K/Akt signaling pathway in cardiac fibrosis</article-title>. <source>Mol Cell Biochem</source><year>2021</year>;<volume>476</volume>:<fpage>4045</fpage>-<lpage>59</lpage>.<pub-id pub-id-type="pmid">34244974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11010-021-04219-w</pub-id></mixed-citation></ref><ref id="ref52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Bai</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Paeoniflorin inhibits mesangial cell proliferation and inflammatory response in rats with mesangial proliferative glomerulonephritis through PI3K/AKT/GSK-3beta pathway</article-title>. <source>Front Pharmacol</source><year>2019</year>;<volume>10</volume>:<fpage>978</fpage>.<pub-id pub-id-type="pmid">31551783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2019.00978</pub-id><pub-id pub-id-type="pmcid">PMC6745507</pub-id></mixed-citation></ref><ref id="ref53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>GSK-3beta activation index is a potential indicator for recurrent inflammation of chronic rhinosinusitis without nasal polyps</article-title>. <source>J Cell Mol Med</source><year>2017</year>;<volume>21</volume>:<fpage>3633</fpage>-<lpage>40</lpage>.<pub-id pub-id-type="pmid">28714566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.13274</pub-id><pub-id pub-id-type="pmcid">PMC5706567</pub-id></mixed-citation></ref><ref id="ref54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>PH</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>YC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>TH</given-names></name><name name-style="western"><surname>Ho</surname><given-names>C</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CL</given-names></name></person-group>. <article-title>The histone demethylase inhibitor GSK-J4 is a therapeutic target for the kidney fibrosis of diabetic kidney disease via DKK1 modulation</article-title>. <source>Int J Mol Sci</source><year>2022</year>;<volume>23</volume>:<fpage>9407</fpage>.<pub-id pub-id-type="pmid">36012674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23169407</pub-id><pub-id pub-id-type="pmcid">PMC9409090</pub-id></mixed-citation></ref><ref id="ref55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>GSK3beta-dependent lysosome biogenesis: An effective pathway to mitigate renal fibrosis with LM49</article-title>. <source>Front Pharmacol</source><year>2022</year>;<volume>13</volume>:<fpage>925489</fpage>.<pub-id pub-id-type="pmid">36225562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.925489</pub-id><pub-id pub-id-type="pmcid">PMC9550195</pub-id></mixed-citation></ref><ref id="ref56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>JH</given-names></name></person-group>. <article-title>Mesangial cells and renal fibrosis</article-title>. <source>Adv Exp Med Biol</source><year>2019</year>;<volume>1165</volume>:<fpage>165</fpage>-<lpage>94</lpage>.<pub-id pub-id-type="pmid">31399966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-981-13-8871-2_9</pub-id></mixed-citation></ref><ref id="ref57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pathomthongtaweechai</surname><given-names>N</given-names></name><name name-style="western"><surname>Chutipongtanate</surname><given-names>S.</given-names></name></person-group><article-title>AGE/RAGE signaling-mediated endoplasmic reticulum stress and future prospects in non-coding RNA therapeutics for diabetic nephropathy</article-title>. <source>Biomed Pharmacother</source><year>2020</year>;<volume>131</volume>:<fpage>110655</fpage>.<pub-id pub-id-type="pmid">32853909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2020.110655</pub-id></mixed-citation></ref><ref id="ref58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tan RZ</surname><given-names>Li JC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>TT</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>X</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Isoliquiritigenin attenuates UUO-induced renal inflammation and fibrosis by inhibiting Mincle/Syk/NF-kappa B signaling pathway</article-title>. <source>Drug Des Devel Ther</source><year>2020</year>;<volume>14</volume>:<fpage>1455</fpage>-<lpage>68</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S243420</pub-id><pub-id pub-id-type="pmcid">PMC7166058</pub-id><pub-id pub-id-type="pmid">32341639</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>